Amarin Corp Plc (AMRN)

[KCSVEN]

That's a pretty flawed analysis. I can use numbers and make things sound anyway I want also. Since Reliant BO was base don a market 10 times smaller than Vascepa's then 10 times the Reliant BO is totally reasonable.

They talk diluted shares but completely ignore inflation in the Reliant BO calculation.

GSK loses Lovaza in 2015 to generics, thus they lose 1 billion in revenue per year or 5 billion in revenue before Vascepa even remotely has a chance to have generics. They could buy AMRN for 5 Billion and worst case scenario they end up recovering the investment.

If Anchor can be sold at even double Marine they make profit, if REDUCE IT comes in they make a killing.

Comparing Lovaza to Vascepa because of the management ties and the fish oil similarities is what the amateurs like to do.

Drug A is and even at time of BO is
-Limited to 4 million people
-Has bad side effects for many people
-No studies show it prevents heart events

Drug B
-Has market potential of 80 million people
-Has almost zero side effects
-Has 1 Japanese study showing prevents Heart event

So who in their right mind compare Drug A to Drug B?